Table 4.

Toxicities of targeted drugs that are potentially mechanism based, including those with a possible role as a pharmacodynamic or predictive biomarker

^aSquamous cell carcinomas and keratoacanthomas were diagnosed in 10%–20% of the patients included in trials with vemurafenib and GSK2118436 (specific BRAF inhibitors in more advanced phases of clinical development).

Abbreviations: EGFR, epidermal growth factor receptor; HER-2, human epidermal growth factor receptor 2; MEK, mitogen-activated protein kinase/extracellular signal–related kinase kinase; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase; VEGF, vascular endothelial growth factor.